JP2004511523A5 - - Google Patents

Download PDF

Info

Publication number
JP2004511523A5
JP2004511523A5 JP2002535670A JP2002535670A JP2004511523A5 JP 2004511523 A5 JP2004511523 A5 JP 2004511523A5 JP 2002535670 A JP2002535670 A JP 2002535670A JP 2002535670 A JP2002535670 A JP 2002535670A JP 2004511523 A5 JP2004511523 A5 JP 2004511523A5
Authority
JP
Japan
Prior art keywords
hormone
cancer
antiprogestin
affected
ability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002535670A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004511523A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/012006 external-priority patent/WO2002032432A1/en
Publication of JP2004511523A publication Critical patent/JP2004511523A/ja
Publication of JP2004511523A5 publication Critical patent/JP2004511523A5/ja
Pending legal-status Critical Current

Links

JP2002535670A 2000-10-18 2001-10-17 細胞におけるアポトシスの誘発のための抗黄体ホルモンの使用 Pending JP2004511523A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24099100P 2000-10-18 2000-10-18
EP00250342 2000-10-18
PCT/EP2001/012006 WO2002032432A1 (en) 2000-10-18 2001-10-17 Use of antiprogestins for the induction of apoptosis in a cell

Publications (2)

Publication Number Publication Date
JP2004511523A JP2004511523A (ja) 2004-04-15
JP2004511523A5 true JP2004511523A5 (es) 2009-01-29

Family

ID=26072952

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002535670A Pending JP2004511523A (ja) 2000-10-18 2001-10-17 細胞におけるアポトシスの誘発のための抗黄体ホルモンの使用

Country Status (29)

Country Link
EP (1) EP1326617B9 (es)
JP (1) JP2004511523A (es)
KR (1) KR100668024B1 (es)
CN (1) CN1209111C (es)
AT (1) ATE334683T1 (es)
AU (2) AU2002223619B2 (es)
BG (1) BG107744A (es)
BR (1) BR0114696A (es)
CA (1) CA2423020C (es)
CY (1) CY1105745T1 (es)
CZ (1) CZ299823B6 (es)
DE (1) DE60121980T2 (es)
DK (1) DK1326617T3 (es)
EA (1) EA010593B1 (es)
EE (1) EE200300157A (es)
ES (1) ES2269492T3 (es)
HK (1) HK1062273A1 (es)
HR (1) HRP20030388A2 (es)
HU (1) HUP0301433A3 (es)
IL (2) IL154976A0 (es)
MX (1) MXPA03002955A (es)
NO (1) NO20031741L (es)
NZ (1) NZ538347A (es)
PL (1) PL360157A1 (es)
PT (1) PT1326617E (es)
SI (1) SI1326617T1 (es)
SK (1) SK4702003A3 (es)
UA (1) UA76729C2 (es)
WO (1) WO2002032432A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
US20080261933A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
EP2136796A2 (en) * 2007-04-23 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
KR102009007B1 (ko) * 2011-10-04 2019-08-08 인비비스 파마슈티컬스 인코포레이티드 항-프로게스틴 민감성 종양을 확인하고 치료하기 위한 방법 및 시스템

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Similar Documents

Publication Publication Date Title
CY1104981T1 (el) Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων
DE602004017151D1 (en) Gonadotropin releasing hormone analoga konjugate mit steroid hormonen
JP2004511523A5 (es)
CY1105745T1 (el) Χρηση της 11βητα-(4-ακετυλφαινυλ)-17βητα-υδροξυ-17αλφα(1,1,2,2-πενταφθοροαιθυλ)οιστρα-4,9-διεν-3-ονη για την παρασκευη ενος φαρμακου για την θεραπεια του καρκινου του μαστου, των ωοθηκων και του ενδομητριου, του μυελωματος και του μηνιγγιωματος
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
BR0008437A (pt) Inibidores esteróides de sulfatase e métodos parafabricação e uso dos mesmos
JP2005501031A5 (es)
HUP0203050A2 (hu) Endometriózis és meddőség kezelésére, valamint a termékenység fokozására alkalmas gyógyszerkészítmények
EA200501739A1 (ru) Композиция, содержащая антагонисты рецептора прогестерона и чистые антиэстрогены, предназначенные для профилактики и лечения гормонзависимых заболеваний
RU2004116167A (ru) Способ повышения эффективности лечения бесплодия, вызванного малыми формами внешнего генитального эндометриоза
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
RU2004132305A (ru) Способ и средство для лечения доброкачественных гиперпластических процессов эндометрия
EA200300480A1 (ru) Применение антипрогестинов для профилактики и лечения гормонозависимых заболеваний
IS7338A (is) Tibólón í meðhöndlun á kvillum tengdum inngjöf á lyfjum sem koma í veg fyrir efnasamtengingu á innrænu estrógeni
RU2003134930A (ru) Противоопухолевое средство бензамид
RU2002120932A (ru) Способ лечения эрозивных поражений гастродуоденальной зоны, резистентных к обычной терапии, у больных бронхиальной астмой
TH58099B (th) การใช้ และสารผสมแอนติโปรเจสตินในการรักษาโรคต่อมลูกหมาก
NO20013901L (no) Umettede kolestanderivater og deres anvendelse for fremstilling av meioseregulerende medikamenter